BioTuesdays

Category - Developments

Dimerix posts positive Phase 2a in CKD

Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200. Dimerix will now progress...

Scientus Pharma Logo

Scientus inks cannabis supply pact with Aphria

Closely-held Scientus Pharma, through its HydRx Farms unit, has entered into a major wholesale purchase agreement with Aphria (TSX:APH; OTCQB:APHQF). Under the accord, Aphria would supply more than 25,000 fully-grown...

Titan Pharmaceuticals Logo

Fortune hails Titan’s ProNeura technology

Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.” The article said Titan’s Probuphine implant for the treatment of...